Allogene Therapeutics (ALLO) vs Wave Life Sciences (WVE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Allogene Therapeutics (ALLO) has outperformed Wave Life Sciences (WVE) over the past year, gaining 6.5% versus a loss of 59.9%. Over five years, WVE leads with a -27.9% price change compared with -91.7% for ALLO. Wave Life Sciences is the larger company by market cap ($616.8 million vs $452.6 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALLO | WVE |
|---|---|---|
| Share price | $1.31 | $3.13 |
| Market cap | $452.59M | $616.76M |
| 1-day change | -2.24% | -1.88% |
| YTD return | -4.38% | -81.59% |
| 1-year return | +6.50% | -59.92% |
| 5-year return | -91.72% | -27.88% |
| EPS (TTM) | $-0.66 | $-1.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $42.73M |
| Revenue growth (YoY) | -100.00% | -60.55% |
| Net income (latest FY) | $-190.89M | $-204.38M |
| Operating margin | — | -504.09% |
| Net margin | — | -478.33% |
| 52-week high | $4.46 | $21.73 |
| 52-week low | $1.04 | $3.04 |
| Distance from 52-week high | -70.63% | -85.60% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +587.02% | +450.16% |
| Average volume | 5.66M | 3.17M |
| Shares outstanding | 345.49M | 197.05M |
| Employees | 150 | 317 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALLO has outperformed WVE by 66.4 percentage points over the past year.
- Wave Life Sciences grew revenue faster in its latest fiscal year (-60.55% vs -100.00%).
About Allogene Therapeutics
ALLO stock →Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.
Healthcare · Biotechnology · 150 employees
About Wave Life Sciences
WVE stock →Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders.
Healthcare · Biotechnology · 317 employees
ALLO vs WVE FAQ
Which is bigger, Allogene Therapeutics or Wave Life Sciences?
Wave Life Sciences (WVE) is larger, with a market capitalization of $616.76M compared with $452.59M for Allogene Therapeutics (ALLO).
Which stock has performed better over the past year, ALLO or WVE?
ALLO returned +6.50% over the past 12 months, compared with -59.92% for WVE (price return, excluding dividends). Past performance does not predict future results.
Are Allogene Therapeutics and Wave Life Sciences in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.